108 results on '"Oskay-Özcelik G"'
Search Results
2. Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries
3. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III
4. A survey of treatment approaches of malignant ascites in Germany and Austria
5. Additional file 1 of Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany
6. Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study
7. Nachsorge des Ovarialkarzinoms
8. Operative Therapie beim Ovarialkarzinomrezidiv: Stellenwert und praktische Aspekte
9. Zytostatikaextravasate: Modernes Management in der Onkologie
10. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial
11. What do ovarian cancer patients expect from their physicians and from the clinical management: a comparative survey of German and Indian patients with ovarian carcinoma.: PO020
12. Teilnahme an klinischen Arzneimittelstudien - warum? Eine motivationspsychologische Langzeituntersuchung von krebskranken Studienteilnehmerinnen: PO553
13. Preoperative serum level of CA 125 as a predictive marker for surgical outcome in advanced primary (POC) and recurrent ovarian cancer (ROC): PO201
14. BRCA1 positive status significantly influences surgical outcome and lymph node involvement in ovarian cancer patients: PP407
15. Breast cancer patientsʼ expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients
16. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
17. Wie ist die Evidenz für die Lyphonodektomie beim frühen Ovarialkarzinom?
18. MONITOR VII: Treatment strategies of low grade ovarian carcinomas – A German survey of the Charité – Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO
19. MONITOR VII – Behandlungsstrategie beim Low-grade Ovarialkarzinom. Eine deutschlandweite Umfrage der Charité – Berlin und Kliniken Essen Mitte mit Unterstützung der NOGGO und AGO
20. Subjektive Krankheitstheorien bei Patientinnen mit Ovarialkarzinom – Ergebnisse einer Patientinnenbefragung
21. Expression III: Erwartungen und Präferenzen von Patientinnen mit Ovarialkarzinom. Eine Umfrage an 585 Patientinnen (NOGGO/Subanalyse der ENGOT ov4-Studie)
22. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III
23. Erste Ergebnisse der Expression V Studie – Berliner Umfrage zu Erwartungen und Wünsche von Patientinnen mit und ohne Migrationshintergrund und gynäkologische Malignome
24. Interimsanalyse der multizentrischen NOGGO Studie – Expression V – Umfrage zu den Erwartungen und Wünschen von Patientinnen mit gynäkologischen Malignomen und mit und ohne Migrationshintergrund
25. 995P - MONITOR VII: Treatment strategies of low grade ovarian carcinomas – A German survey of the Charité – Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO
26. A survey of treatment approaches of malignant ascites in Germany and Austria
27. 956P - Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC)
28. 958P - Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO)
29. What do breast cancer patients (BC) expect from their physicians and from treatment? Results of a german survey in 617 patients
30. 867P - Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses of the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology Ovarian Cancer Working Group
31. Second Cycle of Catumaxomab Treatment in Patients with Malignant Ascites: Results from the Secimas Study
32. First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology.
33. Effect of catumaxomab on EpCAM+ tumor cells in vitro in the presence of immune effector cells from ovarian cancer patients treated with chemotherapy.
34. Are there any molecular biologic factors which explain the poorer prognosis of elderly patients with advanced ovarian cancer?
35. What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients.
36. Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study.
37. Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS).
38. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: Results of a multicenter phase II study of the northeastern German society of gynecological oncology
39. 8029 The expression of CASA in ascites correlates with the overall survival and clinical outcome in patients with ovarian cancer
40. 8002 What is the best schedule of Topotecan? – weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer – a randomized, multicenter trial of the North-Eastern German Society of Gynaecological Oncology (TOWER)
41. 8057 How relevant is the CA-125 monitoring for patients with ovarian cancer in the follow-up? – Results from a multicenter survey in 1060 patients with ovarian cancer
42. 8067 Platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
43. Schedule-Optimierung von Topotecan in der Therapie des Ovarialkarzinoms
44. Was sind die Erwartungen von Pat. mit Ovarial-Ca an die Nachsorge? Finale Ergebnisse einer deutschlandweiten Umfrage an 1040 Pat. – Umfrage an Patientinnen zur Nachsorge beim Ovarialkarzinom
45. Sequentieller Einsatz von Carboplatin gefolgt von Paclitaxel in der First- Line Therapie des Ovarial-Ca – Carboplatin gefolgt von Paclitaxel in der Therapie des Ovarial-Ca
46. Surgical procedures in recurrent ovarian cancer
47. Aktuelle Aspekte der Therapie des platinresistenten Ovarialkarzinoms
48. Sicherheit der Erythropoetingabe in der First-Line Chemotherapie des Ovarialkarzinoms. Ergebnisse einer prospektiven Studie
49. Zytostatikaextravasate
50. Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.